Black Diamond Therapeutics, Inc. BDTX Stock Forecast
AI-powered price prediction and analysis for Black Diamond Therapeutics, Inc. · Total · absolute moveSwitch to Alpha
See BDTX's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (BDTX) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
Where BDTX sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| BDTX Black Diamond Therapeutics, Inc. | ▲ | $119M | 5.1x |
| AMGN Amgen Inc | ▼ | $237.31B | 27.3x |
| GILD Gilead Sciences, Inc. | ▶ | $194.07B | – |
| MRNA Moderna, Inc. | ▲ | $90.58B | – |
| ARGX Argenx Se | ▼ | $53.82B | 22.8x |
| RVMD Revolution Medicines, Inc. | ▲ | $39.04B | – |
| BIIB Biogen Inc. | ▼ | $35.67B | 26.1x |
| BNTX Biontech Se | ▲ | $23.06B | 2.4x |
| EXEL Exelixis, Inc. | ▼ | $15.95B | 18.6x |
| HALO Halozyme Therapeutics, Inc. | ▶ | $14.12B | 28.6x |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.92B | 19.8x |
| TECH Bio-Techne Corp | ▼ | $11.37B | 62.5x |
| QGEN Qiagen N.V. | ▶ | $10.10B | 33.0x |
| RGEN Repligen Corp | ▲ | $9.96B | 255.7x |
| KRYS Krystal Biotech, Inc. | ▶ | $9.63B | 40.8x |
| PCVX Vaxcyte, Inc. | ▲ | $9.48B | – |
| KYMR Kymera Therapeutics, Inc. | ▲ | $9.43B | – |
| IBRX Immunitybio, Inc. | ▲ | $9.29B | – |
| TWST Twist Bioscience Corp | ▲ | $8.76B | – |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.73B | – |
| IMVT Immunovant, Inc. | ▲ | $5.91B | – |
| KOD Kodiak Sciences Inc. | ▲ | $5.84B | – |
| CGON Cg Oncology, Inc. | ▲ | $5.49B | – |
| SRRK Scholar Rock Holding Corp | ▲ | $4.90B | – |
| CRSP Crispr Therapeutics Ag | ▲ | $4.82B | – |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.90B | – |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.75B | – |
| TARS Tarsus Pharmaceuticals, Inc. | ▶ | $3.05B | – |
| DNLI Denali Therapeutics Inc. | ▶ | $3.03B | – |
| LIFE Atyr Pharma Inc | ▲ | $2.62B | – |
| BEAM Beam Therapeutics Inc. | ▲ | $2.57B | 99.7x |
| ADMA Adma Biologics, Inc. | ▼ | $2.52B | 18.1x |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.16B | – |
| VCEL Vericel Corp | ▶ | $2.07B | 109.1x |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.03B | – |
| ALVO Alvotech | ▲ | $1.83B | – |
| NVAX Novavax Inc | ▲ | $1.78B | – |
| VIR Vir Biotechnology, Inc. | ▲ | $1.73B | – |
| IMCR Immunocore Holdings Plc | ▶ | $1.68B | – |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.65B | – |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.60B | – |
| MESO Mesoblast Ltd | ▶ | $1.55B | – |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.28B | – |
| VOR Vor Biopharma Inc. | ▲ | $1.07B | – |
| REPL Replimune Group, Inc. | ▲ | $1.04B | – |
| IMTX Immatics N.V. | ▲ | $1.01B | – |
| JATT Zura Bio Ltd | ▶ | $994M | – |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $969M | – |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $954M | – |
| MGTX Meiragtx Holdings Plc | ▶ | $908M | 12.3x |
| SLBT Sl Science Holding Ltd | ▶ | $873M | – |
| ODTX Odyssey Therapeutics, Inc. | ▶ | $870M | – |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $723M | – |
| PRME Prime Medicine, Inc. | ▲ | $695M | – |
| SANA Sana Biotechnology, Inc. | ▲ | $689M | – |
| AURA Aura Biosciences, Inc. | ▲ | $680M | – |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $664M | – |
| CADL Candel Therapeutics, Inc. | ▲ | $661M | – |
| SLDB Solid Biosciences Inc. | ▲ | $635M | – |
| DBVT Dbv Technologies S.A. | ▼ | $561M | – |
FAQ
Is Black Diamond Therapeutics, Inc. a good stock to buy?
Our AI analyzes Black Diamond Therapeutics, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Black Diamond Therapeutics, Inc. predictions?
For BDTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 8.0%, measured on 358 forecast dates between 2022-08-02 and 2026-07-22 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 400 forecast dates between 2022-08-02 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Black Diamond Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 20, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Black Diamond Therapeutics, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.